Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (go-raise)

Rheumatology (United Kingdom)

Volumn 52, Issue 2, 2013, Pages 321-325

  Van der Heijde, Désirée ^a   Braun, Jürgen ^b   Deodhar, Atul ^c   Inman, Robert D ^d   Xu, Stephen ^e   Mack, Michael E ^e   Hsu, Benjamin ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Ankylosing spondylitis; Anti TNF; Assessment tool; Enthesitis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

12 POINT BERLIN INDEX; 13 POINT MAASTRICHT AS ENTHESITIS SCORE; 17 POINT UNIVERSITY OF CALIFORNIA, SAN FRANCISCO INDEX; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; ENTHESITIS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEALTH STATUS INDICATORS; HUMANS; INJECTIONS, SUBCUTANEOUS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873874141     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes251     Document Type: Article

References (11)

1. Mander M, Simpson JM, McLellan A et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197-202.
2. Inman RD, Davis JC Jr, van der Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402-12.
3. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
4. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
5. Jenkinson TR, Mallorie PA, Whitelock HC et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
6. van der Heijde D, Landewé R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67: 489-93.
7. van der Heijde D, Lie E, Kvien TK et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:1811-8.
8. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
9. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl J Med 2002;346:1349-56.
10. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32.
11. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987;40:171-8.